Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced ...
Genprex (($GNPX)) announced an update on their ongoing clinical study. Study Overview: Genprex is conducting a study titled A Phase 1/2 ...
Advances in cancer immunotherapy from immune checkpoint modulation to adoptive cell transfer of tumour-infiltrating ...
After telegraphing an investigation in November, the FDA has moved to restrict the use of bluebird bio’s gene therapy Skysona in certain patients. The FDA has updated Skysona’s indication, allowing it ...
Biopsy specimen of a glioblastoma with prominent micovascular proliferation (formation of a mulitlayered "glomeruloid tuft", HE stain). (Jensflorian, CC BY-SA 3.0 , via Wikimedia Commons) From Philly ...
Gene therapy represents an innovative approach to treating cancer by directly modifying the genetic material within tumour cells, thereby utilising molecular mechanisms to inhibit tumour growth or ...
In a preclinical study, UC Davis Comprehensive Cancer Center scientists developed a highly targeted gene therapy that could revolutionize treatment for cancers linked to a common herpesvirus, with ...
The Healthy @Reader's Digest on MSN
New Prostate Cancer Treatment Options You Should Know About, From a Urologic Surgeon
A globally-renowned prostate cancer surgeon shares the latest advancements in the field and stresses the importance of early ...
The stock makes the Nasdaq top gainers list today following news on the close yesterday. Genprex is trading at 0.7695, up ...
Scientists have found a new way to stop cancer growth without damaging healthy cells. Researchers from the Francis Crick ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback